Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Dose Escalation shows no benefit compared to continuing ABVD in Hodgkin's lymphoma patients with an interim PET deauville score of 4

View Full Paper
Ask AI
Bookmark
Share

Authors

NNNelson Inácio Pinto NetoANArata NishimotoCPCarolina Pereira

Discussion

Loading...

Member takes

Overview

Retrospective cohort study shows no difference in progression-free survival for Hodgkin's lymphoma patients, suggesting de-escalation may be viable.

Key Points

  • Treatment response was similar for patients continuing ABVD versus escalation to Dacarbazine in Hodgkin's lymphoma patients with a Deauville score of 4.
  • Progression-free survival was not statistically different between the ABVD and escalated therapy groups, with p = 0.2 noted.
  • This retrospective cohort study analyzed clinical and imaging outcomes following interim PET in patients treated for Hodgkin's lymphoma.
  • Implications include the need for a larger cohort to validate findings around treatment de-escalation and response.

Cite This Study

Neto et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d340https://doi.org/10.1182/blood-2025-1854
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Predictors of discordant end-of-treatment PET positivity in advanced-stage classical Hodgkin lymphoma patients with negative interim PET response2025
  2. 2Treatment practices and outcomes of advanced stage classical Hodgkin lymphoma in India: An analysis from the hematology cancer consortium2025
  3. 3Association of PET4 Response With Outcomes of BV-CHP vs CHOP in the ECHELON-2 Trial in CD30+ Peripheral T-cell Lymphoma2025 · 2 citations
  4. 4Interim and end-of-treatment FDG-PET demonstrate limited ability to predict 3-year progression-free survival with nivolumab-AVD in first-line treatment of advanced stage Hodgkin lymphoma: Imaging sub-analysis of Phase 3 S1826 study2025 · 5 citations
  5. 5Enhancing prognostic accuracy in PMBCL: semiquantitative analysis of interim PET/CT scans2025